Survival of melanoma patients with brain metastases treated with ipilimumab and stereotactic radiosurgery
| Autor: | Cody Chiuzan, Keisuke Shirai, Karim Tazi, Amanda R. Hathaway |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Oncology
Adult Male Proto-Oncogene Proteins B-raf medicine.medical_specialty Cancer Research medicine.medical_treatment Ipilimumab Antineoplastic Agents Radiosurgery Cohort Studies Internal medicine medicine melanoma Humans metastasis Radiology Nuclear Medicine and imaging ipilimumab Survival analysis Aged Neoplasm Staging Retrospective Studies Original Research Aged 80 and over business.industry Proportional hazards model Brain Neoplasms Melanoma Hazard ratio Antibodies Monoclonal Brain Retrospective cohort study Middle Aged medicine.disease Survival Analysis Surgery stereotactic Treatment Outcome Cohort Mutation Female business medicine.drug |
| Zdroj: | Cancer Medicine |
| ISSN: | 2045-7634 |
| Popis: | Historically, melanoma with brain metastases has a poor prognosis. In this retrospective medical record review, we report the outcome of patients with stage IV melanoma with brain metastases treated with ipilimumab and brain stereotactic radiosurgery (SRS). All patients with metastatic melanoma treated with ipilimumab from June 2010 to September 2012 were identified and stratified by presence (A) or absence (B) of brain metastases at the time of ipilimumab administration. All patients with brain metastases received SRS. Overall survival (OS) was defined as time from the date of stage IV diagnosis and the time of ipilimumab administration to death or last follow-up. Survival curves were estimated using the Kaplan–Meier method, and Cox proportional hazards model was employed to compute the hazard ratios (HR). Results: Five out of 10 patients in Cohort A and 10 out of 21 patients in Cohort B died as of last follow-up. In Cohort A, median number of lesions treated with SRS was 3. Median survivals from date of stage IV for Cohorts A and B were 29.3 and 33.1 months, respectively (HR = 0.93, P = 0.896). Median survival from cycle 1 ipilimumab was 16.5 and 24.5 months for Cohort A and B, respectively (HR = 1.05, P = 0.931). The 3-year survival rates from the date of cycle one of ipilimumab administration for Cohort A and B were 50% (95% CI: 27–93%) and 39% (95% CI: 19–81%), respectively. Eight of 10 patients in Cohort A maintained a good PS. Survival of patients with melanoma brain metastases treated with ipilimumab combined with SRS may be comparable to patients without brain metastases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text